How to Get Rezdiffra (Resmetirom) in Hawaii

Why Rezdiffra Matters for Hawaii Patients With MASH

Rezdiffra is the first and, as of mid-2026, the only FDA-approved pharmacotherapy targeting MASH with liver fibrosis stages F2 and F3. Before its March 2024 accelerated approval, no drug carried an FDA indication for this disease. Hawaii's geographic isolation and limited hepatology specialist density make understanding access pathways especially relevant for the estimated 30,000+ state residents living with MASH.

The MAESTRO-NASH trial (N=966) randomized adults with biopsy-confirmed MASH and fibrosis stage F1B through F3 to resmetirom 80 mg, 100 mg, or placebo. At 52 weeks, 25.9% of patients receiving 80 mg achieved at least a one-stage improvement in fibrosis without worsening of NASH, compared with 14.2% on placebo [1]. NASH resolution without fibrosis worsening occurred in 29.9% of the 80 mg group vs. 9.7% of the placebo arm [1]. These results established resmetirom as a thyroid hormone receptor-beta (THR-β) agonist with measurable histologic benefit.

Dr. Stephen Harrison, principal investigator of MAESTRO-NASH, stated: "For the first time, we have a therapy that addresses the underlying fibrotic progression of MASH, not just the metabolic parameters surrounding it" [1].

The clinical profile carries practical implications. Resmetirom lowered LDL cholesterol by approximately 16% in the 80 mg group [1], a secondary benefit for MASH patients who frequently carry concurrent dyslipidemia. Monitoring requirements include baseline and periodic liver function tests and lipid panels, which shape the prescribing workflow described below.

Step-by-Step Prescription Process in Hawaii

Getting a Rezdiffra prescription in Hawaii follows a defined clinical pathway. A licensed prescriber (MD, DO, NP with prescriptive authority, or PA) evaluates the patient, confirms MASH diagnosis with fibrosis staging, and submits the prescription to a specialty or compounding pharmacy.

Diagnosis confirmation. The FDA label specifies Rezdiffra for MASH with moderate to advanced hepatic fibrosis (stages F2-F3). Diagnosis typically requires either a liver biopsy or a validated noninvasive combination. The AASLD practice guidance supports the use of FibroScan (vibration-controlled transient elastography) alongside the FIB-4 index as a noninvasive staging approach [2]. A FibroScan liver stiffness measurement between 8.0 and 13.0 kPa generally corresponds to F2-F3 fibrosis when combined with clinical context [2].

Prescriber types. Hawaii Revised Statutes §453 and §457 authorize MDs, DOs, and advanced practice registered nurses (APRNs) with prescriptive authority to prescribe Schedule VI (non-controlled) medications. Physician assistants may prescribe under a supervising physician agreement. Resmetirom is not a controlled substance, so no DEA registration beyond the standard state license is needed.

Prescription routing. Because Rezdiffra is a specialty medication, most commercial plans require the prescription to be filled at a designated specialty pharmacy. Patients should confirm with their insurer which pharmacy network applies. Some patients opt for a 503A compounding pharmacy route, discussed in a later section.

Telehealth Prescribing for Rezdiffra in Hawaii

Hawaii permits telehealth prescribing of Rezdiffra. Hawaii's telehealth statute (HRS §453-1.3) authorizes licensed physicians to establish a patient-provider relationship via synchronous audio-video consultation [3]. This allows Hawaii residents on neighbor islands or in rural O'ahu communities to access hepatology or endocrinology specialists without traveling to Honolulu.

A telehealth visit for Rezdiffra typically includes three components: a clinical history reviewing risk factors (obesity, type 2 diabetes, metabolic syndrome), review of imaging or biopsy results confirming fibrosis stage, and a medication reconciliation to check for drug interactions. THR-β agonists do not carry the CYP3A4 interaction burden of many hepatology drugs, but prescribers should verify concurrent statin doses given resmetirom's LDL-lowering effect [1].

Telehealth platforms operating in Hawaii must hold a valid Hawaii medical license or be registered under the state's out-of-state telehealth registration process. The prescriber must be able to order labs through a Hawaii-accessible laboratory (Quest Diagnostics and Clinical Labs of Hawaii both operate statewide). Lab orders can be placed electronically during the telehealth visit, and results reviewed at a follow-up virtual appointment before the prescription is finalized.

One practical consideration: Hawaii's time zone (HST, UTC-10) means mainland-based telehealth providers may have limited scheduling windows. Patients should confirm appointment availability aligns with their schedule before enrolling with an out-of-state telehealth service.

Required Labs Before Starting Rezdiffra

The FDA prescribing information mandates specific laboratory assessments before initiating resmetirom and during ongoing treatment. Missing these labs will delay prescription fulfillment and may result in prior authorization denial.

Baseline labs (required before first dose):

• Comprehensive metabolic panel (CMP), including ALT, AST, and total bilirubin. The FDA label specifies that treatment should not be initiated if ALT or AST exceeds 5 times the upper limit of normal [4].
• Lipid panel (total cholesterol, LDL, HDL, triglycerides). Resmetirom's THR-β agonism lowers LDL cholesterol, and baseline values are needed to monitor this effect and adjust concurrent statin therapy [1].
• TSH and free T4. Although resmetirom is selective for THR-β and should not significantly affect TSH in most patients, baseline thyroid function establishes a reference point [4].
• FIB-4 index calculation (derived from age, AST, ALT, and platelet count) or FibroScan report documenting fibrosis stage.

Monitoring labs (ongoing):

The label recommends periodic liver function tests. Most prescribers order ALT, AST, and bilirubin at 3 months, 6 months, and then every 6 months thereafter. A lipid panel at 12 weeks helps assess LDL response and informs statin dose adjustments.

In Hawaii, labs can be drawn at any Clinical Labs of Hawaii location (over 30 sites across O'ahu, Maui, Big Island, and Kaua'i) or at Quest Diagnostics patient service centers. LabCorp has limited direct presence in Hawaii but accepts samples through partner draw sites.

Pharmacy Access and 503A Compounding in Hawaii

Rezdiffra is distributed through specialty pharmacy channels. Madrigal Pharmaceuticals uses a limited distribution network, meaning not every retail pharmacy stocks the drug. Patients in Hawaii will typically fill prescriptions through one of two pathways.

Specialty pharmacy fulfillment. National specialty pharmacies such as Accredo, CVS Specialty, and OptumRx ship to Hawaii addresses. Shipping times to Honolulu average 2 to 4 business days via standard carriers. Neighbor island delivery may add 1 to 2 days. Cold chain is not required for resmetirom tablets, which simplifies shipping logistics compared to injectable biologics [4].

503A compounding pharmacies. Hawaii permits 503A compounding pharmacies to operate and ship within the state under Hawaii Administrative Rules §16-95 [5]. A 503A pharmacy compounds a medication pursuant to a valid, patient-specific prescription. This pathway may be relevant if a prescriber determines a dose adjustment outside the commercially available 80 mg and 100 mg tablets is clinically appropriate, though this is uncommon with resmetirom. Out-of-state 503A pharmacies may also ship to Hawaii if they hold the appropriate state-by-state licensure.

Cost considerations. The wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year. Madrigal offers the Rezdiffra Complete co-pay assistance program for commercially insured patients, which may reduce out-of-pocket costs to as low as $0 per month for eligible patients. Uninsured patients may qualify for the Madrigal patient assistance program, though eligibility criteria include income thresholds.

Prior Authorization Requirements in Hawaii

Most commercial insurers and all Medicare Part D plans require prior authorization (PA) for Rezdiffra. Hawaii Medicaid does not cover the drug as of 2026, so Medicaid beneficiaries must explore manufacturer assistance or appeal pathways.

The standard PA documentation package includes:

1. Confirmed MASH diagnosis with fibrosis stage F2 or F3, documented by liver biopsy pathology report or a combination of noninvasive markers (FibroScan plus FIB-4 or NAFLD Fibrosis Score).
2. Baseline lab results showing ALT/AST <5× upper limit of normal.
3. Documentation of metabolic risk factors (BMI, hemoglobin A1c, lipid panel).
4. Prescriber attestation that the patient does not have decompensated cirrhosis (Child-Pugh B or C), which is a contraindication per the FDA label [4].
5. Prior lifestyle intervention documentation. Some insurers require evidence that diet, exercise, or weight management was attempted before approving pharmacotherapy. The AASLD guidance recommends at least 6 months of lifestyle modification, and insurers may reference this benchmark [2].

PA turnaround times in Hawaii vary by insurer. HMSA (Hawaii's dominant commercial plan) typically processes specialty drug PAs within 5 to 7 business days. Kaiser Permanente Hawaii operates an integrated pharmacy model and may process requests faster. UnitedHealthcare and Aetna plans sold on the Hawaii exchange follow their national PA timelines, generally 3 to 5 business days for standard requests and 24 hours for urgent/expedited requests.

If a PA is denied, patients have the right to appeal. Hawaii Insurance Division regulations require insurers to provide an external review option for denied specialty drug claims. The prescriber should submit a peer-to-peer review request, where they discuss the clinical rationale directly with the insurer's medical director.

Hawaii Medicaid and Coverage Gaps

Hawaii Medicaid (Med-QUEST) does not include Rezdiffra on its preferred drug list as of May 2026. This creates a coverage gap for the approximately 400,000 Hawaii residents enrolled in Medicaid managed care plans (AlohaCare, HMSA QUEST, Kaiser, UHC Community Plan).

Medicaid beneficiaries have limited options. The Madrigal patient assistance program may cover the full cost for patients who meet income criteria, typically at or below 400% of the federal poverty level [1]. Patients should also ask their prescriber about submitting a formulary exception request to their Medicaid managed care plan, which requires clinical documentation that no therapeutic alternative exists for MASH with fibrosis. Because resmetirom is the only FDA-approved drug for this indication, the "no alternative" argument carries weight, though approval is not guaranteed.

The American Association for the Study of Liver Diseases (AASLD) has called for broader payer coverage of MASH-directed therapies, noting that "the burden of NASH-related cirrhosis and hepatocellular carcinoma is projected to increase by 82% over the next decade without pharmacologic intervention" [2].

Timeline: From First Visit to First Dose in Hawaii

A realistic timeline helps patients plan. The total time from initial consultation to receiving the first dose of Rezdiffra in Hawaii ranges from 2 to 6 weeks under typical circumstances.

• Week 1: Initial consultation (in-person or telehealth). Labs ordered and drawn.
• Week 1-2: Lab results reviewed. If fibrosis staging requires a FibroScan, scheduling may add 1 to 2 weeks depending on availability (FibroScan is available at Queen's Medical Center, Straub Medical Center, and select neighbor island gastroenterology practices).
• Week 2-3: Prescription submitted. Prior authorization initiated.
• Week 3-4: PA decision received. If approved, prescription routed to specialty pharmacy.
• Week 4-5: Specialty pharmacy ships medication to patient's Hawaii address.
• Week 5-6: First dose taken. Follow-up telehealth or in-person visit scheduled for 8 to 12 weeks.

Delays can occur at the PA stage, especially if the insurer requests additional documentation. Patients can compress the timeline by having all labs and imaging completed before the initial prescriber visit.

Transferring a Rezdiffra Prescription to Hawaii

Patients relocating to Hawaii or splitting time between the mainland and the islands can transfer an existing Rezdiffra prescription. Hawaii Board of Pharmacy rules permit prescription transfers between pharmacies, including interstate transfers, for non-controlled medications. The receiving pharmacy in Hawaii contacts the originating pharmacy to verify and transfer the prescription record.

For specialty pharmacy patients, the process is simpler if both the originating and receiving pharmacies are within the same network (e.g., both are CVS Specialty locations). Cross-network transfers may require a new prescription from the Hawaii-licensed prescriber. Patients should initiate the transfer at least 2 weeks before their current supply runs out to account for shipping times to Hawaii.